Trustees’ Annual Report for the period
From 1[st] January 2024 To 31[st] December 2024
Charity name: Salivary Gland Cancer UK
Charity registration number: 1182762
Objectives and Activities
| SORP reference | ||
|---|---|---|
| Summary of the purposes of the charity as set out in its governing document |
Para 1.17 | Help those affected by rare salivary gland cancers. Advocate for these patients and carers by providing peer support and information about their disease, care and treatment. Promote and assist research into all aspects of salivary gland cancers, including causes, diagnosis, treatments and cures. To educate the public and healthcare communities in all things related to salivary gland cancers, including raising awareness of symptoms. |
| Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts. |
Para 1.17 and 1.19 |
• Supporting the community via in person and virtual meetings for patients, carers and clinicians. • Providing information and increasing awareness via leaflets, meetings, the website, social media and fundraising events. • Raising awareness of these cancers and their unmet need via speaking, submitting materials and attending meetings and conferences. • Expansion of the network to support all salivary gland cancer types. • Expansion of the charity’s outputs to provide more research and disease specific information. |
| Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit |
Para 1.18 | The trustees have kept in mind the charity Constitution and the guidance from the Charities Commission in all of its’ activities. The governance documents of the Charity are regularly reviewed at Trustee meetings. The charity’s “8 aims” are regularly published via our social media outlets and are the foundation for all activities and |
decisions within the charity. The trustees ensure the prioritisation of activities is aligned with these aims.
Additional information (optional) You may choose to include further statements where relevant about:
| SORP reference | ||
|---|---|---|
| Policy on grant making | Para 1.38 | Following our first call for grant applications in August 2023, we subsequently awarded £36,600 to two projects. Both projects are now underway and £21,000 was paid out across of these initiatives in 2024. The Board receives regular progress updates regarding these grants. |
| Policy on social investment including program related investment |
Para 1.38 | |
| Contribution made by volunteers |
Para 1.38 | We are hugely grateful for the support and contribution we received from our volunteers assisting us in specific projects and outputs, sharing their stories on social media channels, and ‘on the day’ physical support at our events. |
| Other |
Achievements and Performance
| SORP reference | ||
|---|---|---|
| Summary of the main achievements of the charity, identifying the difference the charity’s work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole. |
Para 1.20 | • Bringing together those living with salivary gland cancers We continued to host bi-annual hybrid (in person/virtual) meetings during 2024, supporting attendees with travel bursaries for patients and their carers where needed. The hybrid structure of our events has facilitated strong attendance from our community across the country and internationally. In March 2024 we hosted a gathering in Manchester and October 2024’s event was in London. We provided regular communications, newsletters and webinars to the network. We continued to produce our video series, releasing recordings of the presentations at our hybrid meetings to ensure we reach as many people as possible. We also continued to add patient stories on social media and on our website. |
| 2024 marked our 5 year anniversary and the |
|---|
| publishing of our 5 year impact report, “The |
| Story So Far.” The report focused on how |
| the collaboration between patients and |
| clinicians has been very impactful since the |
| charity’s inception and highlights what has |
| been achieved over this period. |
| • Raising awareness amongst the |
| general public and the clinical |
| community |
| We continue to work to increase our visibility |
| among the clinical and patient network by |
| attending and presenting at various |
| conferences and events. |
| In February we presented at the CRUK CNS |
| forum and at the 2ndAnnual Clinical |
| Outsourcing Group conference. We |
| attended the LifeArc Translational Science |
| Summit in April where we engaged in |
| various discussions on how translational |
| science can potentially bridge the gap |
| between basic research and clinical |
| applications. The event featured |
| presentations and valuable insights from |
| leading scientists, experts, policy makers |
| and innovators. |
| In May we visited Westminster and attended |
| the Cancer52 launch of their manifesto to |
| transform outcomes for people with rare |
| cancers. We hosted a stall and spoke at the |
| Oncology and Professional Care |
| Conference. In September we attended the |
| ESMO Congress in Barcelona and in |
| November we hosted a stall and presented |
| at the Swallows International Head and |
| Neck Cancer Conference. |
| During the year, SGC UK joined the |
| PRONTO Study Management Group, who |
| are investigating the role of proton beam |
| therapy for patients needing adjuvant |
| radiotherapy. We also became members of |
| the Northern Head and Neck Alliance. |
| Our Patient and Public Involvement (PPI) |
| work has continued to grow and develop in |
| 2024. We are regularly called upon to input |
| into the design of research studies, provide |
| feedback on trial protocols, help researchers |
| develop lay summaries of their work and |
| bring the perspective of those with lived |
| experiences to discussions. |
| Many fund raising events, both large and |
| small, have taken place during the year, |
| notably our supporters’ participation in the |
|---|
| Brighton and London Marathons. |
| • Bringing together the patient, clinical |
| and research communities to help |
| drive forward research and |
| improvements in treatments |
| Following the closure of the National Cancer |
| Research Institute (NCRI) and SGC UK |
| taking forward the research activities in |
| relation to salivary gland cancer, the |
| Research Working Group has been very |
| active during 2024. |
| Our inaugural meeting in March 2024 was |
| attended by clinicians, researchers and |
| patient advocates from all around the UK |
| and beyond. Knowledge and expertise were |
| shared, and four key areas of research were |
| identified. Workstreams are now in place to |
| address these areas which also align with |
| the charity’s aims. |
Additional information (optional) You may choose to include further statements where relevant about:
Achievements against Para 1.41 objectives set Performance of fundraising Para 1.41 activities against objectives set Investment performance Para 1.41 against objectives Other
Financial Review
| Review of the charity’s financial position at the end of the period |
Para 1.21 | As at 31stDecember 2024 the charity held a cash balance of £68,381, (prior year £104,832). The charity had an in-year deficit of £36,451 (prior year surplus £56,736). The charity received income of £37,336 (prior year £90,250) from donations raised through fund raising initiatives and personal legacies. The charity’s accounts for the year have been independently reviewed with no issues raised. TBC Despite an in-year deficit, the charity’s financial position remains robust. There was a material increase in donations in 2023, allowing sufficient brought forward funds to support the initiatives in 2024, including the issuance of two grants. |
|---|---|---|
| Statement explaining the policy for holding reserves stating why they are held |
Para 1.22 | The cash balance is held in order to support the overall objectives of the charity. Cash is used to cover operating expenses, develop the charity’s presence through marketing and fund specific patient/clinician events. Cash held is also the source funds for the grants we have issued and for any other grant making opportunities that may arise. |
| Amount of reserves held | Para 1.22 | £68,381 in cash. |
| Reasons for holding zero reserves |
Para 1.22 | Not applicable |
| Details of fund materially in deficit |
Para 1.24 | Not applicable |
| Explanation of any uncertainties about the charity continuing as a going concern |
Para 1.23 | There are no uncertainties around the charity’s ability to continue as a going concern. The Board carefully consider the on- going running costs of the charity when assessing the funds available for grants and other events. |
Additional information (optional) You may choose to include further statements where relevant about:
| The charity’s principal sources of funds (including any fundraising) |
Para 1.47 | |
|---|---|---|
| Investment policy and objectives including any social investment policy adopted |
Para 1.46 | |
| A description of the principal risks facing the charity |
Para 1.46 | The Board maintains a Risk Register for the charity. This document highlights governance, operational, financial, compliance and external risks and the |
mitigants in place. The Board reviews the Risk Register periodically. Other
Structure, Governance and Management
| Description of charity’s trusts: |
||
|---|---|---|
| Type of governing document (trust deed, royal charter) |
Para 1.25 | The charity is governed by its Constitution. |
| How is the charity constituted? (e.g unincorporated association, CIO) |
Para 1.25 | The charity is a Charitable Incorporated Organisation. |
| Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees |
Para 1.25 | Trustees must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees. When selecting trustees, the charity trustees have regard to the skills, knowledge and experience needed for the effective administration of the CIO. The Board periodically reviews a detailed skills matrix to identify any gaps and regularly discusses the structure and composition of the Board to ensure its ongoing effectiveness as a governing body. |
Additional information (optional) You may choose to include further statements where relevant about:
Policies and procedures Para 1.51 adopted for the induction and training of trustees The charity’s organisational Para 1.51 structure and any wider network with which the charity works Relationship with any related Para 1.51 parties Other
Reference and Administrative details
| Charity name | Salivary Gland Cancer UK |
|---|---|
| Other name the charity uses | |
| Registered charity number | 1182762 |
| Charity’s principal address | International House 36-38 Cornhill City of London London EC3V 3NG |
Names of the charity trustees who manage the charity
| 1 2 3 4 6 7 8 9 10 11 12 13 14 15 |
Trustee name | Office (if any) | Dates acted if not for whole **year ** |
Name of person (or body) entitled to appoint trustee (ifany) |
|---|---|---|---|---|
| Emma Jane Kinloch |
Trustee and Chair | The Board | ||
| Dr Robert Metcalf | Trustee | The Board | ||
| Shane Lisa Draper | Trustee and Chief Financial Officer |
The Board | ||
| Olorunkemi Fausat Akanke Olaiya |
Treasurer | **Non-Board role | The Board | |
– Corporate trustees names of the directors at the date the report was approved
Director name
Name of trustees holding title to property belonging to the charity
Trustee name Dates acted if not for whole year
Funds held as custodian trustees on behalf of others
Description of the assets Not applicable held in this capacity Name and objects of the Not applicable charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for Not applicable safe custody and segregation of such assets from the charity’s own assets
Additional information (optional)
Names and addresses of advisers (Optional information)
| Type of | Name | Address |
|---|---|---|
| adviser |
Name of chief executive or names of senior staff members (Optional information)
Exemptions from disclosure
Reason for non-disclosure of key personnel details
Other optional information
Declarations The Iruslaes declare that they havo approved the trustees. report abov•. Slgned on behalf of the charity's trustees Slgnaturels Full namelsl Posltlon (og Secretary, Chalr. etc) Emma Jane Kin1( Shane Lisa Draper Chair Chief Financial Officer Dats OLS
CHARITY COMMISSION Foq ENGLAND AND WAIES Recei tsand ments accounts CC16a To l•iJ•r 2014 31xt tl•c•rnb•w 2•24 Section A Recei ts and ments un$1¢2ed Totsltunds AI RK•l l• p<r SubloL•llGmss income TAR) J?.x .210 A? A¥•i •nd Inv•#m•t ••l. S1•1 37.jm J?.J 10,260 i• JJ.io• In • q 17.J7• 17.Y• 1J,7¥0 ln trrtry tréDrrt# Ir mwrkn 1.$10 1.$1• 717 73.7•7 ,014 A• AM•1 •nd Inv•Atm•nl 73,717 7J.717 33.514 14•iof rec•lptsip•ym•nts) AS Tmnth b•tw••n lund• A6 Ctth funds l•Bt y•w•nd C•8h luftdt 114s y•r•nd J6.451 ,736 104.•32 104.J32 60.J81 48.098 104.832 Section B Statement of assets and liabilities at the end of the eriod fund• B1 Calh fw Toi•lush fw*s fund• fund B2 Other mon•tary u••ts
03 In¥ts•I ••••l• B4 A•••ts r•tslMdfvr th• ¢hrlty'# uA• s1on•O byon• knJ•t•••C47